Jazz, AbCellera collaborate on cancer antibodies
Analysis based on 10 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026
The collaboration between Jazz Pharmaceuticals and AbCellera is expected to have a positive impact on the biotechnology and pharmaceutical markets. It signals potential advancements in cancer treatment, particularly for GI cancers and solid tumors, which could lead to new revenue streams for both companies and improved patient outcomes.
Jazz Pharmaceuticals and AbCellera announced a preclinical research collaboration, option, and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. This collaboration will utilize AbCellera's antibody discovery engine to create optimized development candidates for various gastrointestinal (GI) cancers and other solid tumors. Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment for a third within 12 months. Jazz Pharmaceuticals has the exclusive option to develop and commercialize therapeutic antibodies resulting from these programs. AbCellera will receive $56 million in upfront payments for the first two programs, an additional $28 million upon initiating the third, and is eligible for up to $792 million per program in option fees, development, regulatory, and commercial sales milestone payments, plus tiered royalties on net sales.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard